Mann mit Smartphone und Tablet (Symbolbild).
Dienstag, 11.07.2023 07:45 von | Aufrufe: 93

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGTX, AMED, FRG, DHC

Mann mit Smartphone und Tablet (Symbolbild). © metamorworks / iStock / Getty Images Plus / Getty Images

PR Newswire

NEW YORK, July 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Sigilon Therapeutics, Inc. (NASDAQ: SGTX)'s sale to Eli Lilly and Company. Under the terms of the agreement, Eli Lilly would acquire all outstanding shares of Sigilon for $14.92 per share in cash payable at closing, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $111.64 per share in cash. If you are a Sigilon shareholder, click here to learn more about your rights and options.

Amedisys, Inc. (NASDAQ: AMED)'s sale to Optum for $101.00 per share. If you are an Amedisys shareholder, click here to learn more about your rights and options.  

Franchise Group, Inc. (NASDAQ: FRG)'s sale to members of the senior management team of Franchise Group led by Brian Kahn, the Company's Chief Executive Officer, and a consortium including B. Riley Financial, Inc. and Irradiant Partners, for $30.00 in cash per share. If you are a Franchise Group shareholder, click here to learn more about your rights and options.  

Diversified Healthcare Trust (NASDAQ: DHC)'s sale to Office Properties Income Trust for 0.147 shares of Office Properties for each common share of Diversified Healthcare. Upon closing of the proposed transaction, Diversified Healthcare shareholders will own approximately 42% of the combined company. If you are a Diversified Healthcare shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.


ARIVA.DE Börsen-Geflüster

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-sgtx-amed-frg-dhc-301873977.html

SOURCE Halper Sadeh LLP

Werbung

Mehr Nachrichten zur Amedisys Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News